Aging comes down, in part, to a simple problem: the body gets worse at cleaning up after itself. Cells that should undergo apoptosis sometimes get stuck in a halfway state. They stop dividing, yet they refuse to die. These are called senescent cells, and popular articles like to nickname them "zombie cells". They pile up with age, and the whole idea behind senolytics is built around them.

What senescent cells are

Cellular senescence starts out as a defense. When a cell racks up DNA damage or risks turning cancerous, it permanently exits the cell cycle. The trouble is that it doesn't go anywhere. A senescent cell keeps living and keeps secreting a whole set of signals. That set is labeled the SASP, the senescence-associated secretory phenotype: inflammatory cytokines, chemokines, growth factors, and enzymes that break down the surrounding matrix.

In a young body the immune system locates and clears these cells. With age the clearing slows down, the SASP smolders as low-grade inflammation, and neighboring healthy cells start to senesce too. In mice, even a small load of senescent cells transplanted into a young animal worsened physical function. That is what turned them into a target.

How senolytics work

The word "senolytics" appeared around 2015. The logic runs like this: if these cells won't die on their own, push them over the edge without harming the healthy ones. It turns out senescent cells survive for a reason. They switch on anti-apoptotic defenses, the so-called SCAPs. Among them are the BCL-2 protein family, the PI3K/AKT pathway, the p53/FOXO4 axis, and several tyrosine kinases.

A senolytic blocks one of those routes. A healthy cell can do without it, while a senescent cell that was leaning on it tips into apoptosis. That explains the dosing pattern that sets senolytics apart from most drugs: not daily, but in short bursts. The approach is called "hit and run". One shove past the edge is enough, so the compound doesn't need to stay in the system.

Dasatinib and quercetin

The first combination described as senolytic was dasatinib plus quercetin, D+Q for short. Dasatinib is a cancer drug, a tyrosine kinase inhibitor. Quercetin is a plant flavonoid. On their own each is weak; together they cover a wider set of SCAPs and hit different kinds of senescent cells.

There is early human data on D+Q, and it deserves a sober read. Small pilot studies ran in idiopathic pulmonary fibrosis and in diabetic kidney disease. In the second, skin and fat biopsies really did show a drop in senescent-cell burden after a few days of dosing. The signal matters, but the samples were tiny and nobody tracked long-term outcomes. Clinical benefit for any specific disease has not been proven yet.

Fisetin

Fisetin is another flavonoid, abundant in strawberries. In 2018 a research group screened dozens of natural compounds and found fisetin among the most active senolytics in mice. It also extended their healthy lifespan. In some assays it looked more selective than quercetin. Clinical trials are running now, including at Mayo Clinic, but there are no final human results.

Peptides are a separate line of work. FOXO4-DRI is designed to break the bond between FOXO4 and p53 inside a senescent cell. Once p53 is freed, the cell goes into apoptosis. In old mice this brought back fur and improved kidney function, and the animals held up longer on a treadmill. The data are still preclinical.

What follows from this

Senolytics are an interesting and fast-growing area, but the field is young. The strong results are mostly in animals, and the human data amount to short pilots. Dosing and the safety of long courses remain open questions, as does the choice of real endpoints for trials. Dasatinib carries serious side effects, and "natural" does not mean "safe": both quercetin and fisetin affect how the liver metabolizes drugs.

At Longeva we supply individual senolytic compounds for research use. If the peptide track interests you, start with the reference page on FOXO4-DRI. The same catalog also lists an adjacent compound for studying metabolism and aging, SLU-PP-332. These are materials for lab work, not medicines. There is no treatment or dosing advice here, and none of the compounds is intended for human consumption.

Research compounds from this review in our catalog: FOXO4-DRI, SLU-PP-332.